Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

0.6497 +0.0044 (+0.68%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

August 07, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

June 20, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

June 13, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Host Investor Roundtable Q&A

June 12, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

May 08, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 ↗

May 03, 2024

ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

April 25, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

April 18, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying ↗

April 04, 2024

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

March 28, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 05, 2024

Via Benzinga

ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

February 09, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 06, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

January 04, 2024

From Aldeyra Therapeutics, Inc.

Via Business Wire

Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study ↗

December 19, 2023

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in

Via Benzinga

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

December 19, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

December 18, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

3 Stocks at the Forefront of Personalized Medicine Trend ↗

December 05, 2023

Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly

Via InvestorPlace

FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study ↗

November 28, 2023

The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reproxalap, an investigational drug

Via Benzinga

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

November 27, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 01, 2023

Gainers

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 01, 2023

Via Benzinga

What's Going On With Aldeyra Therapeutics Stock? ↗

November 01, 2023

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares are trading higher Wednesday after the company announced that it entered into an exclusive opti

Via Benzinga

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is One of Wednesday Morning’s Most Active Stocks

November 01, 2023

Via Investor Brand Network

Why Are Stocks Up Today? ↗

November 01, 2023

Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.

Via InvestorPlace

Topics Economy

Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? ↗

November 01, 2023

Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 01, 2023

Via Benzinga

Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap

November 01, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

NASDAQ:ALDX Long Term Investor Alert: Investigation over Potential Wrongdoing at Aldeyra Therapeutics, Inc. ↗

October 17, 2023

San Diego, CA -- (SBWIRE) -- 10/17/2023 -- Certain directors of Aldeyra Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.

Via SBWire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.